Fred Sultan Honored with Austin LGBT Bar Association Award of Excellence

18 October 2017

Gardere litigation attorney Frederick W. Sultan IV was honored with the Austin LGBT Bar Association’s Award of Excellence at the organization’s third annual scholarship fundraiser and awards gala, Sculpting the Future, Oct. 18. Sultan was recognized for his leadership roles within the organization, having served as vice chair from 2014-15 and chair from 2015-16. Sultan also appeared on the Oct. 2017 cover of Texas Lawyer to discuss LGBT issues and advocacy within the legal community.

The annual gala raises money to provide scholarships to two law students at Texas law schools with demonstrated commitments to the LGBT community or LGBT legal issues.

Sultan, a member of the firm’s litigation practice group, helps individuals and businesses throughout Texas and the U.S. with commercial litigation and appeals involving a broad range of business disputes, including employment, contract, business tort and trade secret-related claims.

People

Related News

View All Posts

25 July 2024 In the News

Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’

Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”

24 July 2024 In the News

Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO

Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.

24 July 2024 In the News

Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’

Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”